Drug intelligence / Profile preview

ELI-301

Development stage: Preclinical
Lead developer: Hangzhou Yili Pharmaceutical
Modality: Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ELI-301 is a preclinical-stage theranostic radiopharmaceutical developed by Eli Radiopharma for the treatment and imaging of solid tumors. It is designed as a versatile platform that can be labeled with different radionuclides depending on the clinical requirement: Gallium-68 (⁶⁸Ga) for diagnostic PET imaging, or Lutetium-177 (¹⁷⁷Lu) and Actinium-225 (²²⁵Ac) for targeted radiotherapy. By utilizing these isotopes, ELI-301 aims to provide a "see-and-treat" approach, allowing for the identification of tumor lesions and subsequent delivery of therapeutic radiation. The specific molecular target of the ELI-301 ligand has not been disclosed by the sponsor.

Other names: ELI-301ELI301ELI 301

Beyond the preview

Go deeper on ELI-301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ELI-301.

Explore the full profile